Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar ...

Background: Neovascular age-related macular degeneration (AMD) has a poor prognosis if left untreated, frequently resulting in legal blindness. Ranibizumab is approved for treating neovascular AMD.

Lucentis' main patents are not due to expire in Europe until next year, but Samsung Bioepis and Biogen are now poised to roll out the drug as soon the intellectual property on the drug lapses.

It cites an “anticompetitive agreement” in the market for Lucentis active ingredient, the anti-VEGF antibody ranibizumab. Specifically, the ACGM claims that the companies entered into a ...

Teva was established as the European commercialisation partner of FYB201, Formycon's biosimilar to ranibizumab (Lucentis).

WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal ...

Homeopathy Homeopathic Medicine Market Expected To Achieve A Strong 6. 47%CAGR, To Reach USD 32. 03 Billion By 2032 The increasing incidence of chronic diseases, such as arthritis, asthma, and ...

Biogen (NASDAQ:BIIB – Get Free Report) had its price target decreased by stock analysts at Wells Fargo & Company from $190.00 ...

Updates on commercial insights and readiness plans for sozinibercept in wet AMDOpthea management to present in New York City on Tuesday, January ...

Sanders博士的职业生涯亮点包括担任Prism Vision Group的董事会成员，以及最近担任美国视网膜专科医师学会主席。他的丰富背景包括担任Lucentis®（一种重要的湿性年龄相关性黄斑变性（湿性AMD）治疗药物）的主要研究员。随着EyePoint推进其湿性AMD全球3期关键试验并报告最近糖尿病黄斑水肿（DME）2期试验的积极中期数据，他的经验预计将特别有益。 InvestingPro ...

In 2024, the Rx IP Update team at Smart & Biggar reported on a number of developments in Canadian life sciences IP and ...

After hours: 7:09:39 p.m. EST ...